1. Home
  2. WVE vs GSBD Comparison

WVE vs GSBD Comparison

Compare WVE & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

N/A

Current Price

$4.89

Market Cap

957.7M

Sector

Health Care

ML Signal

N/A

Logo Goldman Sachs BDC Inc.

GSBD

Goldman Sachs BDC Inc.

N/A

Current Price

$9.65

Market Cap

974.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
WVE
GSBD
Founded
2012
2012
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
957.7M
974.8M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
WVE
GSBD
Price
$4.89
$9.65
Analyst Decision
Strong Buy
Sell
Analyst Count
16
2
Target Price
$29.81
$9.00
AVG Volume (30 Days)
3.4M
854.4K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
13.49%
EPS Growth
N/A
87.27
EPS
N/A
0.09
Revenue
$3,704,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$85.67
N/A
P/E Ratio
N/A
$110.89
Revenue Growth
149.43
N/A
52 Week Low
$4.65
$8.36
52 Week High
$21.73
$11.43

Technical Indicators

Market Signals
Indicator
WVE
GSBD
Relative Strength Index (RSI) 38.60 47.68
Support Level N/A $8.81
Resistance Level $6.33 $9.83
Average True Range (ATR) 0.23 0.20
MACD -0.02 -0.06
Stochastic Oscillator 22.03 9.55

Price Performance

Historical Comparison
WVE
GSBD

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

Share on Social Networks: